JAK2 and essential thrombocythemia: In JAK2 V617F+ cell lines, as well as in primary cells from patients with PV and ET, givinostat selectively inhibited the growth and proliferation of JAK2 V617F+ cells, down-regulating the mutant protein and blocking downstream signaling [109].